Search Videos by Topic or Participant
Browse by Series:

Current Trends in the Treatment of CRC

Panelists Johanna Bendell, MD, Sarah Cannon; Marwan Fakih, MD, City of Hope; Heinz-Josef Lenz, MD, USC; John L. Marshall, MD, Georgetown; Alan
Published: Tuesday, Jun 10, 2014
For High-Definition, Click
Immunotherapies have not gained traction in colorectal cancer (CRC), despite their promise in lung cancer, renal cell carcinoma, and melanoma, John Marshall, MD, notes. In general, about 60% of patients with CRC do not have a targetable mutation, suggesting these patients might be ideal for immunotherapy, Alan Venook, MD, believes.

Johanna Bendell, MD, notes that several practice-changing trials were presented at the 2014 GI Cancers Symposium that demonstrated the importance of testing for BRAF mutations and performing an expanded KRAS analysis in all patients with CRC. The identification of additional markers for response remains an unmet need, according to Heinz-Josef Lenz, MD. Along these lines, biomarkers and the utilization of molecular test results are a major theme for research in GI cancers, suggests Marwan Fakih, MD.


Slider Left
Slider Right
For High-Definition, Click
Immunotherapies have not gained traction in colorectal cancer (CRC), despite their promise in lung cancer, renal cell carcinoma, and melanoma, John Marshall, MD, notes. In general, about 60% of patients with CRC do not have a targetable mutation, suggesting these patients might be ideal for immunotherapy, Alan Venook, MD, believes.

Johanna Bendell, MD, notes that several practice-changing trials were presented at the 2014 GI Cancers Symposium that demonstrated the importance of testing for BRAF mutations and performing an expanded KRAS analysis in all patients with CRC. The identification of additional markers for response remains an unmet need, according to Heinz-Josef Lenz, MD. Along these lines, biomarkers and the utilization of molecular test results are a major theme for research in GI cancers, suggests Marwan Fakih, MD.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x